Novo Nordisk A/S

NOVO B

DK0062498333

Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows: - diabetes and obesity treatment products (92.6%); - rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc. Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).

Employees

69,260

Sector

Pharmaceuticals

Calendar

2024-11-06 - Q3 2024 Earnings Release

More about the company

Analysis / Opinion

NOVO NORDISK : Q2 miss; recent market fears should be capitalised on by long-term investors

August 07, 2024 at 09:48 am EDT

Lars Fruergaard Jorgensen, CEO of Novo Nordisk on guidance, Wegovy and US Market

August 07, 2024 at 06:07 am EDT

Novo Nordisk doesn't disappoint

January 31, 2024 at 10:48 am EST

More Strategies

Ratings

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

922.10DKK

Average target price

967.54DKK

Spread / Average Target

+4.93%

Consensus

Profit revisions

Estimate revisions

Quarterly earnings, Rate of surprise

Company calendar

Market Closed - Nasdaq Copenhagen Other stock markets 11:20:00 2024-09-16 am EDT			5-day change	1st Jan Change
922.10 ^DKK	+0.39%		+3.96%	+32.09%

Sep. 16	Korro Bio Partners With Novo Nordisk to Develop Genetic Medicines	MT
Sep. 16	Korro Bio, Inc Announces Collaboration with Novo Nordisk to Develop Two Therapeutic Candidates	CI

Korro Bio Partners With Novo Nordisk to Develop Genetic Medicines	Sep. 16	MT
Korro Bio, Inc Announces Collaboration with Novo Nordisk to Develop Two Therapeutic Candidates	Sep. 16	CI
Eli Lilly invests $1.8 billion in Ireland sites to scale up Alzheimer's, obesity drug production	Sep. 12	RE
NOVO NORDISK : Deutsche Bank keeps its Buy rating	Sep. 12	ZD
Roche shares drop on side effects result in early-stage obesity pill trial	Sep. 12	RE
Health Care Down on Cyclical Bias -- Health Care Roundup	Sep. 11	DJ
Sector Update: Health Care Stocks Narrowly Mixed Premarket Wednesday	Sep. 11	MT
Novo Nordisk's Experimental Obesity Pill Could Be More Effective With Extended Use	Sep. 11	DJ
NOVO NORDISK : JP Morgan reiterates its Buy rating	Sep. 11	ZD
NOVO NORDISK : Gets a Neutral rating from UBS	Sep. 11	ZD
Novo Nordisk Reports Positive Results of Phase 3a Trial of Anti-Obesity Drug Liraglutide in Children	Sep. 11	MT
Health Care Up on Defensive Bias -- Health Care Roundup	Sep. 10	DJ
Weight-loss market to see 16 new drugs by 2029, report estimates	Sep. 10	RE
European Equities Traded in the US as American Depositary Receipts Decline in Friday Trading; Index Set to End Week 3.7% Lower	Sep. 06	MT
Novo Nordisk to present advances in diabetes treatment	Sep. 06	CF
Are thematic ETFs useless?	Sep. 06
Veeva Systems: leader in cloud solutions for the life sciences industry	Sep. 06
NOVO NORDISK : Gets a Neutral rating from Berenberg	Sep. 06	ZD
Health Care Declines as Risk Aversion Weighs - Health Care Roundup	Sep. 05	DJ
European Equities Traded in the US as American Depositary Receipts Lower in Thursday Trading	Sep. 05	MT
NOVO NORDISK : JP Morgan remains its Buy rating	Sep. 05	ZD
How to find and check an Ozempic batch number	Sep. 05	RE
Ozempic shortages will hit some EU countries only - Novo Nordisk	Sep. 04	RE
Ozempic shortages in EU will not affect all member states - Novo Nordisk	Sep. 04	RE
US will still pay at least twice as much after negotiating drug prices	Sep. 03	RE

Novo Nordisk A/S

Equities